Related Experiment Video

Updated: Jun 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

E17K substitution in AKT1 in prostate cancer

J L Boormans1, H Korsten, A C J Ziel-van der Made

  • 1Department of Urology, Erasmus University Medical Centre, 3000 CA, Rotterdam, The Netherlands. j.boormans@erasmusmc.nl

British Journal of Cancer
|April 22, 2010
PubMed
Abstract

Insights

The AKT1 E17K mutation is rare in prostate cancer, occurring in 1.4% of cases. This genetic alteration appears linked to a better clinical outcome for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The phosphatidylinositol 3-kinase (PI3K)-AKT pathway plays a crucial role in cancer development.
  • Mutations in AKT1, PIK3CA, and PIK3R1 are frequently observed in various cancer types.
  • The AKT1 E17K substitution activates AKT1 independently of PI3K signaling.

Purpose of the Study:

  • To investigate the prevalence and clinical significance of AKT1 and PI3K pathway mutations in prostate cancer.
  • To determine if specific mutations in AKT1, PIK3CA, or PIK3R1 are associated with prostate tumor characteristics or clinical course.

Main Methods:

  • Mutational profiling of AKT1, PIK3CA, and PIK3R1 hotspots was performed on prostate tumor samples.
  • Analysis included both primary and recurrent tumor specimens.

Main Results:

  • The AKT1 E17K mutation was detected in 1.4% of prostate cancer cases.
  • This mutation was associated with a favorable clinical course.
  • No association was found between AKT1 E17K and specific tumor growth patterns.
  • Activating mutations in PIK3CA or PIK3R1 were not identified in the studied prostate cancer cohort.

Conclusions:

  • The E17K substitution in AKT1 is an infrequent finding in prostate cancer.
  • This mutation appears to correlate with a positive clinical outcome.
  • The AKT1 E17K mutation is not linked to specific tumor histology in prostate cancer.

More Related Videos

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration06:21

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration

Published on: April 27, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...